Envista Holdings Corp. (NVST)

Over the past six months, Envista Holdings Corp. announced its third-quarter 2025 results and released its 2024 Sustainability Report on October 29, 2025. On February 5, 2026, Envista reported its fourth-quarter 2025 results. On May 6, 2026, Envista announced strong first-quarter 2026 results, with sales increasing 14.4% year-over-year to $705.5 million and core sales growing by 9.5%. Net income more than doubled, and adjusted diluted EPS rose by 50% to $0.36. Envista completed the acquisition of Versah, which is expected to be accretive to growth, margins, and EPS. On May 5, 2026, the board authorized a new $300 million stock repurchase program through December 31, 2029. JPMorgan raised its price target on Envista to $29 from $26 on May 7, 2026, while maintaining a Neutral rating. The stock's price increased by 51.83% over the last 12 months and 18.85% year-to-date as of May 5, 2026. However, there was a recent pullback, with the stock declining 6.4% over the last 7 days and 4.0% over the last 30 days as of May 9, 2026. Macroeconomic uncertainty, tariffs, and the impact of China's volume-based procurement (VBP) policy are noted as ongoing challenges and risks.

The dental industry, in which Envista Holdings Corp. operates, exhibits a seasonal pattern where the first quarter typically sees sequential declines in revenue compared to the fourth quarter. The dental market is generally characterized by predictable demand and resilience, but it can also be economically sensitive, with macroeconomic weakness and policy actions potentially impacting pricing and volumes.

Envista Holdings Corp. is a global dental products company that develops, manufactures, and markets dental consumables, equipment, and services. It operates in the Healthcare sector, specifically in the Medical Instruments & Supplies industry, through two segments: Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment focuses on dental implant systems, orthodontic bracket systems, aligners, and lab products, featuring brands like Nobel Biocare and Ormco. The Equipment & Consumables segment offers dental equipment and supplies, including digital imaging systems and restorative materials, with brands like Kerr and DEXIS. Envista has a portfolio of over 30 trusted dental brands.

Envista Holdings Corp. serves dental professionals in over 130 countries globally. In 2024, the Specialty Products & Technologies segment generated 42% of its sales from North America, 27% from Western Europe, 5% from other developed markets, and 26% from emerging markets. For the Equipment & Consumables segment in the same year, North America accounted for 69% of sales, Western Europe for 12%, other developed markets for 4%, and emerging markets for 15%.

Envista Holdings Corp. maintains a strong brand reputation, supported by its portfolio of over 30 trusted dental brands, including Nobel Biocare, Ormco, and Kerr. Its products and solutions are utilized in an estimated 90% of dental clinics worldwide. In 2024, Envista refreshed its leadership team and introduced a new strategy focused on accelerating growth, advancing operational excellence, and investing in its workforce. The company invested an additional $25 million in commercial coverage, clinical education, and new product development in 2024, training over 120,000 clinicians. Recent product launches and the acquisition of Versah have further strengthened its implant offering. Envista's Q1 2026 results highlighted strong growth across orthodontics, diagnostics, and consumables, contributing positively to its reputation.

Envista Holdings Corp. has a significant institutional ownership base, including major shareholders like BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Institutional investors hold approximately 68.54% of the company's stock. Individual owners and insiders include Lin Tan, Lihui Song, Money Victory Ltd, and Yan Tan.